NYSE:IQVIqvia Stock Price, Forecast & News

Iqvia's stock was trading at $125.42 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, IQV shares have decreased by 6.6% and is now trading at $117.14. View which stocks have been mosted impacted by Coronavirus.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iqvia in the last year. There are currently 17 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Iqvia.

Iqvia is scheduled to release its next quarterly earnings announcement on Wednesday, May 6th 2020. View our earnings forecast for Iqvia.

Iqvia Holdings Inc (NYSE:IQV) released its quarterly earnings results on Wednesday, February, 12th. The medical research company reported $1.74 EPS for the quarter, beating the consensus estimate of $1.72 by $0.02. The medical research company had revenue of $2.90 billion for the quarter, compared to the consensus estimate of $2.85 billion. Iqvia had a return on equity of 17.65% and a net margin of 1.72%. The firm's revenue for the quarter was up 7.7% compared to the same quarter last year. During the same quarter last year, the company posted $1.50 EPS. View Iqvia's earnings history.

Iqvia issued an update on its first quarter earnings guidance on Friday, April, 3rd. The company provided earnings per share guidance of $1.46-1.51 for the period, compared to the Thomson Reuters consensus estimate of $1.59. The company issued revenue guidance of $2.71-2.74 billion, compared to the consensus revenue estimate of $2.81 billion.

17 brokers have issued 12 month price objectives for Iqvia's shares. Their forecasts range from $110.00 to $200.00. On average, they expect Iqvia's stock price to reach $156.81 in the next year. This suggests a possible upside of 33.9% from the stock's current price. View analysts' price targets for Iqvia.

News stories about IQV stock have been trending very negative recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Iqvia earned a daily sentiment score of -3.3 on InfoTrie's scale. They also gave news headlines about the medical research company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutIqvia.

Iqvia saw a decrease in short interest in March. As of March 13th, there was short interest totaling 2,777,500 shares, a decrease of 22.2% from the February 27th total of 3,570,000 shares. Based on an average daily trading volume, of 1,500,000 shares, the days-to-cover ratio is currently 1.9 days. Currently, 1.5% of the company's stock are sold short. View Iqvia's Current Options Chain.

Some companies that are related to Iqvia include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), Charles River Laboratories Intl. (CRL), PPD (PPD), Exelixis (EXEL), PRA Health Sciences (PRAH), BTG (BTGGF), Syneos Health (SYNH), Medpace (MEDP), National Research (NRC), Precigen (PGEN), Intrexon (PGEN), STARPHARMA HOLD/S (SPHRY) and Luna Innovations (LUNA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Iqvia investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Paypal (PYPL), Allergan (AGN) and UnitedHealth Group (UNH).

Iqvia trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."

Iqvia's stock is owned by a number of retail and institutional investors. Top institutional investors include McGuire Investment Group LLC (0.05%), State of Alaska Department of Revenue (0.04%), Callahan Advisors LLC (0.01%), Foundations Investment Advisors LLC (0.00%) and Global Trust Asset Management LLC (0.00%). Company insiders that own Iqvia stock include Ari Bousbib, Canada Pension Plan Investment, Cpp Investment Board Private H, Group Holdings (Sbs) Advis Tpg, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Robert Parks, Ronald A Rittenmeyer and W Richard Staub. View institutional ownership trends for Iqvia.

IQV stock was sold by a variety of institutional investors in the last quarter, including McGuire Investment Group LLC, Callahan Advisors LLC, and Global Trust Asset Management LLC. Company insiders that have sold Iqvia company stock in the last year include Ari Bousbib, Group Holdings (Sbs) Advis Tpg, John Connaughton, Kevin C Knightly, Michael J Evanisko, and Michael R Mcdonnell. View insider buying and selling activity for Iqvia.

IQV stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, and Foundations Investment Advisors LLC. View insider buying and selling activity for Iqvia.

Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of IQV stock can currently be purchased for approximately $117.14.

Iqvia has a market capitalization of $22.53 billion and generates $11.09 billion in revenue each year. The medical research company earns $191 million in net income (profit) each year or $5.94 on an earnings per share basis. Iqvia employs 67,000 workers across the globe. View additional information about Iqvia.

The official website for Iqvia is http://www.iqvia.com/.

Iqvia's mailing address is 4820 EMPEROR BLVD, DURHAM NC, 27703. The medical research company can be reached via phone at 919-998-2000 or via email at [email protected]